Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $33.00.
Several research analysts have recently weighed in on ODTX shares. TD Cowen started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating for the company. Wedbush assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Wall Street Zen cut Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Finally, Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating for the company.
Check Out Our Latest Research Report on Odyssey Therapeutics
Odyssey Therapeutics Price Performance
Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, research analysts anticipate that Odyssey Therapeutics will post -5.97 EPS for the current fiscal year.
Odyssey Therapeutics Company Profile
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.
See Also
- Five stocks we like better than Odyssey Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
